rethinkTHC Search
Menu
Study breakdown

The Endocannabinoid System May Be Involved in Huntington's, Parkinson's, Schizophrenia, and Tremor

ReviewModerate evidence
The takeaway

A comprehensive review found the endocannabinoid system is involved in movement control, memory, and appetite, and may contribute to the pathology and offer therapeutic targets for Huntington's, Parkinson's, schizophrenia, and tremor.

Read this if you want to understand how the endocannabinoid system relates to major neurological diseases.

CB1 receptor loss in Huntington's occurs early and may contribute to involuntary movements

What the researchers found

This review synthesized the rapidly growing understanding of the endocannabinoid system's role in neurological disease.

The endocannabinoid system, consisting of two receptors (CB1, CB2) and two endogenous ligands (anandamide, 2-AG), is involved in normal movement control, memory formation, and appetite regulation. As this physiological role became clearer, evidence emerged that the system may be disrupted in several neurological diseases.

For Huntington's disease, loss of CB1 receptors in the basal ganglia occurs early and may contribute to the characteristic involuntary movements. For Parkinson's disease, endocannabinoid levels appear altered, and cannabinoids may help treat levodopa-induced dyskinesia. For schizophrenia, the interaction between cannabinoid and dopamine systems may contribute to psychotic symptoms. For tremor, cannabinoids showed direct therapeutic potential.

The review identified an array of potential therapeutic approaches: cannabinoid agonists, antagonists, and compounds that modify endocannabinoid synthesis, uptake, or metabolism.

Why it matters

This review reframed neurodegenerative diseases through the lens of the endocannabinoid system, suggesting that cannabis-based medicines might not just treat symptoms but address underlying pathophysiology in some conditions.

The numbers in context

Two receptors (CB1, CB2). Two endogenous ligands (anandamide, 2-AG). Four diseases reviewed: Huntington's, Parkinson's, schizophrenia, tremor.

How the study worked

Comprehensive narrative review of endocannabinoid system involvement in four neurological conditions, covering receptor distribution, endocannabinoid levels, and potential therapeutic targets.

What this study cannot tell us

Much of the evidence was preclinical at the time of publication. The therapeutic applications proposed were largely theoretical. The complexity of the endocannabinoid system means that simple agonist or antagonist approaches may have unintended effects.

How to read the evidence

A comprehensive narrative review synthesizing preclinical and early clinical evidence. Provides a strong conceptual framework but many proposed applications were speculative.

When this study was published

Published in 2001. Research on endocannabinoid involvement in neurodegenerative diseases has expanded substantially.

The bigger picture

The concept of endocannabinoid system dysfunction in neurological disease has expanded substantially since this review. Research into CB1 receptor loss in Huntington's and endocannabinoid modulation in Parkinson's continues to be active.

Questions still open

  • Have cannabinoid-based treatments been developed for any of these conditions? Is CB1 receptor loss a cause or consequence of Huntington's pathology? Could endocannabinoid-boosting drugs be safer than direct agonists?

Common questions

Is the endocannabinoid system involved in neurological diseases?
Yes. This review found evidence of endocannabinoid system disruption in Huntington's, Parkinson's, schizophrenia, and tremor, suggesting both pathological involvement and therapeutic opportunities.
Could cannabis treat these diseases?
Potentially. The review identified cannabinoid agonists, antagonists, and endocannabinoid-modifying compounds as potential therapeutic approaches, though most evidence was preclinical at the time.

Read the original research

The role of cannabinoids in neurodegenerative diseases.

Progress in neuro-psychopharmacology & biological psychiatry, 25(4), 743-65

Citation

Glass, M. (2001). The role of cannabinoids in neurodegenerative diseases.. Progress in neuro-psychopharmacology & biological psychiatry, 25(4), 743-65.

Explore the wider topic